adesso (ADN1) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
8 Jul, 2026Executive summary
Sales revenues grew 12% year-over-year to €709.5 million in H1 2025, driven by organic expansion and strong demand for digitalization services.
EBITDA increased 34% to €37.2 million, with margin improving to 5.2% from 4.4% in H1 2024.
Net loss narrowed to €-6.0 million from €-9.9 million, and EPS improved to €-0.88 from €-1.51 year-over-year.
Employee headcount rose 7% to 10,794 FTEs, supporting business growth.
The company reaffirmed its full-year guidance, expecting revenue of €1.35–1.45 billion and EBITDA of €105–125 million.
Financial highlights
Domestic sales grew 14% while international sales rose 6% year-over-year.
Gross profit increased 10% to €598.0 million; personnel costs up 10% to €493.7 million.
Free cash flow was negative at -€80.8 million, down 61% year-over-year.
Net working capital rose 10% to €226.0 million; equity ratio declined to 21.5%.
Operating cash flow was €-44.2 million, mainly due to higher trade receivables and contract assets.
Outlook and guidance
Full-year 2025 revenue forecast remains €1.35–1.45 billion, with EBITDA of €105–125 million and margin target above 7.6%.
Earnings expected to be weighted toward H2 2025 due to more working days and increased IT spending, especially in the public sector.
Management expects higher earnings in H2 2025, supported by order backlog and new opportunities in defense and infrastructure.
IT services and software markets are expected to grow steadily, with sector-specific growth outpacing general economic trends.
Latest events from adesso
- Sales up 11% in Q1 2025; margin recovery and stronger H2 earnings expected.ADN1
Q1 2025 TU9 Jul 2026 - 14% sales growth and margin gains in 2024 set the stage for further expansion in 2025.ADN1
H2 20248 Jul 2026 - Sales up 16% to €631.1m, but negative EPS and EBITDA guidance cut amid margin pressure.ADN1
H1 20248 Jul 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 202611 May 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025